IGF2BP2 and ovarian cancer: Interestingly, the autoantibody against IGF2BP1 was also detected at a comparable percentage (26.5%), and it is unknown whether the autoimmune responses to IGF2BP1 and IGF2BP2 are correlated in ovarian cancer patients.